Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Targeting complement system to treat myasthenia gravis
Ruksana Huda
, Erdem Tüzün
, Premkumar Christadoss
Microbiology And Immunology
Research output
:
Contribution to journal
›
Article
›
peer-review
29
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting complement system to treat myasthenia gravis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
Autoantibodies
20%
Autoimmune Disease
20%
Autoimmunity
80%
Complement Component 3
20%
Complement Component C1q
20%
Complement Factor
20%
Complement Inhibitor
60%
Complement Membrane Attack Complex
20%
Complement System
100%
Cytokine
20%
Decay-Accelerating Factor
20%
Eculizumab
20%
Experimental Autoimmune Myasthenia Gravis
20%
Immunoglobulin Class
20%
Immunosuppression
20%
Immunosuppressive Drug
20%
Muscle
20%
Myasthenia gravis
100%
Neuromuscular Junction
40%
Peptides
20%
Ribonucleic Acid
20%
Susceptibility
20%
Neuroscience
Autoantibodies
16%
Autoimmune Disease
16%
Complement Component C1q
16%
Complement Component C3
16%
Complement Factor
16%
Complement Membrane Attack Complex
16%
Complement System
100%
Cytokine
16%
Decay Accelerating Factor
16%
Eculizumab
16%
Immunoglobulin Class
16%
Immunosuppression
16%
Immunosuppressive Drug
16%
Myasthenia gravis
100%
Neuromuscular Junction
33%
Peptide
16%
Receptor
16%
Side Effect
16%
Small Interfering RNA
16%
Keyphrases
Myasthenia Gravis Treatment
25%